Alembic Pharma Q2 net up 1% to Rs 121 crore

The company had posted a net profit of Rs 119.83 crore in the corresponding period of the previous fiscal

Image
Press Trust of India New Delhi
Last Updated : Nov 07 2017 | 1:55 PM IST
Alembic Pharmaceuticals on Tuesday reported a 1.44 per cent increase in consolidated net profit at Rs 121.56 crore for the second quarter ended September 30, mainly on account of decline in total income.

The company had posted a net profit of Rs 119.83 crore in the corresponding period of the previous fiscal.

Total income declined by 9.44 per cent to Rs 796.96 crore for the quarter under review against Rs 880.05 crore in the same period a year ago, Alembic Pharmaceuticals said in a BSE filing.

Also Read

Alembic Pharmaceuticals MD Pranav Amin said: "The US formulations business continues to face price erosion on some key products, however, the India branded business is showing signs of recovery".

During the quarter, the company's international formulations business revenue fell 25.56 per cent to Rs 262 crore while US formulations business revenue fell 29.36 per cent to Rs 190 crore.

Alembic Pharmaceuticals said its India formulations business grew 6 per cent to Rs 385 crore.

Shares of Alembic Pharmaceuticals Ltd were trading 0.59 per cent higher at Rs 515.50 on BSE.
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

First Published: Nov 07 2017 | 1:55 PM IST

Next Story